Cosmo Pharmaceuticals SPA – Trademark Portfolio

Entity Type: 03

Cosmo Pharmaceuticals SPA holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. The owner is based in Lainate.

Via C. Colombo 1

Lainate I-20020 , IT

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

COSMO
COSMO
Abandoned 2007

Trademark Classifications

Cosmo Pharmaceuticals SPA's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

45
Legal & Security Services (1 filing)

Legal services; security services for the protection of property and individuals

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Cosmo Pharmaceuticals SPA have?

Cosmo Pharmaceuticals SPA has 1 U.S. trademark filed with the USPTO.

What trademark classes does Cosmo Pharmaceuticals SPA file in?

Cosmo Pharmaceuticals SPA files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What is Cosmo Pharmaceuticals SPA's trademark registration success rate?

Cosmo Pharmaceuticals SPA has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.